HelixTalk - Rosalind Franklin University's College of Pharmacy Podcast · Sean P. Kane, PharmD; Khyati Patel, PharmD

147 - Key Recommendations from the 2022 AHA/ACC/HFSA Heart Failure Guidelines

·48 min·4 clips

Dr. Cain and Dr. Patel dive into the 2022 heart failure guidelines, fresh off the press with key clinical pearls.

This episode provides a clinical summary of the 2022 AHA/ACC/HFSA heart failure guideline update. The hosts are Dr. Cain and Dr. Patel, pharmacists and faculty at Rosalind Franklin University's College of Pharmacy. They aim to distill the most important clinical pearls from the comprehensive new document. The guidelines represent a full A-to-Z update, the first since 2013, prompted by mounting evidence for new drug classes. A key driver for the update was the need to formally incorporate SGLT2 inhibitors into treatment recommendations. The document was released in April 2022 and signifies a shift in how future updates will be managed. Moving forward, the plan is to update specific sections or "chunks" as new evidence emerges, rather than issuing periodic full revisions. The hosts note the guideline committee included over 100 contributors. They structure the discussion around the updated stages of heart failure, from Stage A (at risk) to Stage D (advanced). A major focus is the revised pharmacotherapy recommendations for heart failure with reduced ejection fraction (HFrEF). The discussion details the new foundational "four pillar" drug classes recommended for most HFrEF patients. One significant change is the formal elevation of SGLT2 inhibitors to a cornerstone of therapy alongside traditional agents. The guidelines introduce a new treatment algorithm emphasizing rapid, sequential initiation of these foundational therapies. The hosts explain the concept of "guideline-directed medical therapy" (GDMT) and its goal to reduce hospitalizations and mortality. They highlight specific guidance on managing patients with heart failure with preserved ejection fraction (HFpEF), an area with historically fewer proven treatments. The episode covers updated recommendations for devices like implantable cardioverter-defibrillators (ICDs) in certain patient populations. Practical insights include discussion on how to prioritize which drugs to start first in a decompensated patient. The tone is exclusively educational and clinical, designed for healthcare professionals. The style is a structured, conversational dialogue between two expert pharmacists reviewing a dense guideline document. This episode is essential for pharmacists, pharmacy students, cardiology nurses, and primary care providers managing heart failure. Listeners seeking broad patient stories or non-clinical health discussions should skip this highly technical, guideline-focused episode.

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from HelixTalk - Rosalind Franklin University's College of Pharmacy Podcast